Doses of 0.5, 1.0, and 2.0 g of cefotiam were infused intravenously over a 15-min period in a crossover fashion to eight volunteers. Doses of 1.0 and 2.0 g were infused intravenously over periods of 30 and 60 min in a double crossover fashion to another eight volunteers. Serum concentrations fell rapidly from peak levels between 30 and 170 ,ug/ml at the end of the infusion to less than 1.0 pg/ml within 6 h after all regimens. The terminal half-life in plasma varied between 0.6 and 1.1 h. The slopes of the time-concentration curves with the different regimens showed different half-life data. The urinary excretion of cefotiam was mostly completed within 4 h of the beginning of drug administration. The pharmacokinetics of cefotiam were dose dependent. With the 2-g dose, the peak plasma concentrations and the values for the area under the curve were more than twice the values observed with 1 g; decreasing values of plasma clearance were observed with higher doses. Injection of cefotiam caused no immediate discomfort or reaction at the infusion site.
active than cefoxitin, cefuroxime, cefoperazone, moxalactam, and cefotaxime against staphylococci (9). As part of the development of Antibiotic assay. An agar well diffusion method was used for the bioassay (2). All serum and urine samples were thawed simultaneously immediately before assay and were processed on the same day. The assay employed Bacillus subtilis ATCC 6633 (spore suspension; Difco Laboratories) and brain heart infusion agar (Oxoid Ltd.), pH 7.4. All serum standards were diluted in pooled human serum. Urine standards were prepared in phosphate buffer (pH 7.4). All determinations were done in triplicate.
Pharmacokinetic analysis. Since the relation between the plasma concentration levels and the applied doses is nonlinear over most of the observed time period, the usual compartment models with linear kinetics do not adequately describe the pharmacokinetic behavior of cefotiam. A tentative two-compartment model with the Michaelis-Menten type of nonlinear elimination (8) Statistical analysis. The relation between the specific area (AUC per dose), the proportion of urinary excretion, the dose, and the duration of infusion were examined by variance analysis and regression analysis with the usual statistical models and test procedures.
RESULTS
The plasma concentration data are summarized in Tables 1 and 2 . Individual plasma concentrations varied considerably in the first hour of blood sampling, especially with the 15-and 30-min infusions. The peak concentrations, obtained at the end of the infusion period, increased with increases in dose. This increase was higher than the ratio of the doses, especially with 2 g for all infusion durations and all volunteers. Plasma concentrations fell rapidly after the end of infusion. Within 4 to 6 h after infusion began, serum levels were below 1 ,Lg/ml. The pharmacokinetic parameters of cefotiam are summarized in Table 3 . Cefotiam was rapidly excreted in urine. At 2 h after infusion began, over 50% of the drug was excreted with all dosage regimens. The urinary excretion was almost completed 4 h after the beginning of administration, with individual variability between 45 and 84% of the dose given. The subjects did not experience any adverse reactions to the drug, and no skin rashes were noted.
DISCUSSION
The pharmacokinetics of cefotiam were found to be dose dependent. The peak plasma concentration and the AUC were more than doubled with higher doses, in particular with the 2-g dose. This effect was found to be statistically significant (comparison between 1 and 2 g at 1% level) for all infusion durations investigated. Consequently, decreasing values of plasma clearance were observed with higher doses. This might be due to the saturation of tubular secretion, which is assumed to participate in the elimination of cefotiam (clearance of cefotiam being higher than that of creatinine). This dose effect seems to be important only with respect to the rate and not to the total amount of cefotiam elimination. No evidence of drug accumulation after repeated administration, however, was reported in previous studies (6) . The place of cefotiam in the current broad cephalosporin armamentarium is difficult to assess at the present time. A critical comparative appraisal of the pharmacokinetics, toxicology, and clinical efficacy will first be necessary. 
